Summary
The antifungal market is steadily growing and fungal infections is today the third most common hospital-acquired infection. The global market is estimated to be worth more than $3 billion USD. Fungal infections have emerged as a growing threat to human health. Two important reasons for this are the number of HIV infected patients and the increasing number of patients treated with cancer chemotherapy drugs. This has formed an ever-expanding number of immuno-compromised individuals at risk for opportunistic infections. As a result several companies have searched for novel molecular targets for new antifungal drugs, by using modern genomic approaches. The goal of a safe prophylactic antifungal therapy may not be far away from being realized, and a success would definitely provide significant revenues.
This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials. Moreover, you will find an up to date outlook of the collaborative landscape of fungal drug discovery. BioSeeker has also investigated the ongoing development of promising screening and assay technologies of importance for further development of new antifungal drugs.
We place special emphasis on glycosylphosphatidylinositol (GPI) anchoring, ABC phospholipid translocators, elongation factor-2 and calcineurin. Extensive scientific research is being conducted in these areas and important breakthroughs are expected earlier than for other novel targets. Many novel targets for antifungal therapy are in early stages of research and development (research, preclinical and phase I studies), and will take at least five to ten years to reach the market. This 80+ page report focuses on recent achievements made in antifungal target discovery and screening assays used to identify novel lead antifungal compounds. BioSeeker Group has identified an array of companies involved in this development and their recent activities are described.
Topics considered in this report are:
Research: identified targets & new assays for drug screening
Clinical trials: Ongoing studies of potential antifungal drugs
Patents: selected near term key patents
Partnerships: key collaborations for success
Companies mentioned in this report:
Abbott Laboratories, Advanced Bio-Technologies , Anadys, ARIAD Pharmaceuticals, Inc, Arrow Therapeutics , AstraZeneca, Aventis , Basilea Pharmaceutica AG, Bayer-AG, Bioqual Inc., Bristol-Myers Squibb, Celera , Demegen, Discovery Technologies, Dyadic , Eisai Co Ltd, Eli Lilly, Elitra, Essential Therapeutics, Fujisawa Pharmaceutical Co, Genelabs, GlaxoSmithKline, GPC Biotech AG, Isis Innovation Ltd, Janssen Pharmaceutica, LG Chemical, Merck, MerLion Pharma, Microbia Inc., Millennium Pharm Inc, Mycologics, Neutec Pharma Plc, Novartis, Novo Nordisk AS, Pfizer, Pharmacia Corp., Pliva Pharmaceutical, Roche, Rosetta Inpharmatics Inc., Wyeth (American Home Prod), Sankyo Co., Ltd, Spirogen, Toyama Chemical Co., Ltd., Tularik Inc., VDDI Pharmaceuticals, Versicor Ltd, Xencor, Inc, Xenova Ltd, Xoma (US) LLC
|
